









Key Operational Measures	2004	Target 20	05	Actual 2005
Organic revenue growth	1%	1-2%	\checkmark	2%
Ordinary EBITA margin	16%	15-16%	\checkmark	16%
Cash conversion	126%	95-105%	\checkmark	106%
Key Financial Measures				
Free Cash Flow	€456mln	± €300mln	\checkmark	€351mln
ROIC %*	7%	6-7%	\checkmark	7%
Ordinary diluted EPS	€1.02	€0.92-€1.01	\checkmark	€1.06





























	Strate	gy &	Rest	ruct	uring	Imp	act			
	EUR Million	20 Original Target	03 Actual	20 Original Target	04 Actual	20 Original Target	05 Actual	2006 Target	To Original Target	tal Guidance
	Product development spend	N/A	200	200 +50 (CC=235)	220	200 +70 (CC=255)	250	270	± 800 (incr. 200 3 yr period)	± 800 (incr. 200 3 yr period)
No.	Non-exceptional restructuring expenses	N/A	N/A	40	25	30	42	30		
-	Exceptional restructuring expenses	100	96	40	44	10	20	-	± 215	± 260
	FTE reductions	500	521	500	724	400	358	200	± 1600	± 1800
1	Total cost savings	20	29	40	70	80	100	120	100-110	150-160 run-rate
(🜏 Wolters Kl	uwer				200	5 Results	March 1, 2	2006 - Amsterd	lam 21



-	2006 Outlook	
	Deliver stronger growth	 Continued investments in products and platforms Launch more new products Strengthen customer relationships and industry partnerships
	Execute restructuring	 Complete LTRE restructuring Continue build out of Shared services; Global Platform, SAP, Off-shoring Continue data center consolidation
	Extend positions in highest return markets	 Health: Integrate acquisitions and expand positions CFS: Extend litigation support / market position Tax & Accounting: Global expansion
	Commitment to thoroughly know	v and understand our customers
4	The Profession	al's First Choice
	Wolters Kluwer	2005 Results March 1, 2006 - Amsterdam 23

Vivision	Organic Revenue Growth
Health	3-5%
Corporate & Financial Services	4-6%
Tax, Accounting & Legal	3-4%
Legal, Tax & Regulatory Europe	0-1%
Education	1-2%
Wolters Kluwer	2-3%

Key Operational Measures	2003	2004	2005	2006*
Organic revenue growth	-2%	1%	2%	2-3%
Ordinary EBITA margin	18%	16%	16%	16.5-17.0
Cash conversion	109%	126%	106%	95-105%
Key Financial Measures				
Free cash flow	€393mln	€456mln	€351mln	± €350m
ROIC %**	7%	7%	7%	7%
Ordinary diluted EPS	€1.18	€1.02	€1.06	€1.18-€1.





EUR Million	2005	2004	Actual Currencies %	Constant Currencies %	Organi Growt %
Revenues	3,374	3,261	3	3	2
Ordinary EBITA	533	516	3	3	(1)
Ordinary EBITA margin %	16	16			
EBITA margin %	15	14			
Ordinary Net Income	327	307	7	7	
Ordinary diluted EPS	€1.06	€1.02	4	4	
Free cash flow	351	456			

EUR Million	2005	2004				
Revenue	3,374	3,261				2005
Ordinary EBITA	533	516		EUR Millions	2005 Revenues	Ordina EBITA
Ordinary EBITA margin %	16	16		Health	656	104
Exceptional items	(20)	(44)		CFS	496	104
EBITA	513	472		TAL	621	122
EBITA margin %	15	14		LTRE	1,292	193
Amortization	(81)	(65)		Education	309	59
Operating income	432	407		Corporate	-	(45)
Income from investments	5	6		Total	3,374	533
Financing results	(103)	(97)				
Results from disposals	4	74		ancing resuli an last year c		
Share of profit associates	3	1		39 on the de		
Income (before tax)	341	391				
Taxation on income	(80)	(80)		sult on dispo		
Net Income	261	311	the SD	e merger of t	en Hagen (± Stam
Attributable to:			50	0		
Equity holders of the parent	260	311				
Minority interest	1		1			

EUR Million	2005	2004	
Net income attributable to equity holders	260	311]
Amortization of intangibles	81	65	
Taxation on amortization	(29)	(25)	
Results on disposals (after tax)	2	(73)	
Exceptional restructuring expense / disposal income (after tax)	13	29	
Ordinary Net Income	327	307	
Ordinary diluted EPS	€1.06	€1.02]
Weighted average number of shares	302	296]
Weighted average diluted shares	317	310	1

EUR Million	2005	2004		Increas	e in no	on-cur	rent a	issets
Total non-current assets	3,805	3,293		related		(5		
Total current assets	1,635	1,729		 Acc PCi 	, Nolis		eAgosi	.111,
Total current liabilities	(2,562)	(1,934)		– Cur	rency	effect	t (stro	nger S
Working capital	(927)	(205)	. •	Total g due to				
Capital Employed	2,878	3,088		net inc		ei 03	uollai	anu
Total group equity	1,099	710						
Total non-current liabilities	1,436	2,093						
Deferred tax liabilities	80	35		Reduced Net Debt				bt
Employee benefits	250	217		2614	2821	2664		
Provisions	13	33	2	2014		2004	1900	
Total Financing	2,878	3,088						1527
Ratios	2005	2004						
Net debt / Equity	1.5	2.2	1	999 2000	2001	2002	2003	2004
Net debt / Ordinary EBITDA	2.6	2.4						

EUR Million	2005	2004	
Operating Profit	432	407	
Amortization & Depreciation	172	168	Lower Cash flo operations due
Exceptional restructuring expense	20	44	- Reduced cont
Autonomous movements in working capital	30	107	from working movements
Cash Flow from Operations	654	726	 Financing costs
Paid Financing costs	(99)	(62)	due to first cou
Paid corporate income tax	(83)	(83)	interest payme new €700 millio
Appropriation of restructuring provisions	(51)	(60)	issued in 2003
Other	8	8	
Cash Flow from Operating Activities	429	529	

EUR Million	2005	2004	
Cash Flow from Operating Activities	429	529	
Net capital expenditure on property, plant and equipment	(86)	(73)	 Higher Capital expenditure due to l'
Net Acquisition spending	(357)	(56)	spend in LTRE
Net receipts from disposal activities	13	(5)	 Higher acquisition spending is mainly due
Dividends received	8	-	DeAgostini acquisitio
Cash from derivatives	83	35	Cash from derivatives
Cash Flow from Investing Activities	(339)	(99)	 realized swap gains €83 million
Exercise of share options	11	-	Dividend 2004 57% sto
Movement in (long-term) loans	(347)	(65)	versus 49% over 2003
Movement in bank overdrafts	46	-	
Dividend payments	(69)	(81)	
Cash Flow from Financing Activities	(359)	(146)	

EUR Million	2005	2004	
Cash flow from operating activities	429	529	
Cash flow from investment activities	(339)	(99)	-
Cash flow from financing activities	(359)	(146)	-
Net Cash Flow	(269)	284	Strong Cash Flo
Cash and cash equivalents as at Jan. 1	687	404	4
Exchange differences on cash equivalents	10	(1)	386 363 400 393
Cash and Cash Equivalents as at Dec. 31	428	687	
Cash flow from operating activities	429	529	
Capital expenditure fixed assets	(86)	(73)	1999 2000 2001 2002 2003 20
Dividends received	8	-	
Free Cash Flow	351	456	

EUR Million	2005	2004	05/04	Working Capital Development, A2003-A2005 (in EUR constant currencies)
Inventories	14	9	5	Feb March Apr May Jun Jul Aug Sep Oct -100,000
Trade debtors	(68)	57	(125)	- 200,000
Other debtors	13	(3)	16	40000
Deferred income	30	19	11	-500,000
Trade creditors	49	65	(16)	Strong Worki
Other short-term liabilities	(8)	2	(10)	Capital Manage
Increase/(Decrease)	30	149*	119	
* Pension payment of €42 million, cause. statement.	s difference wi	ith prior yea	ar Cash flow	23 ³⁴

T	2005 Acquisiti	ons	
-	Health (\pm C12 million)	■ Boucher	September 8, 2005
	CFS (±€25 million)	 PCi Entyre Tripoint AmeriSearch 	January 31, 2005 October 4, 2005 October 6, 2005 July 6, 2005
7	TAL (±€4 million)	 Best Case Solutions 	December 30, 2005
	LTRE (±€78 million)	 DeAgostini Professionale / UTET Nolis, Eon, Rosetti CEDAM, remaining 50% shares were acquired 	May 25, 2005 April 22, June 9, August 24, 2005 December 28, 2005
	Total	Annualized revenues of ±€120 million	2005 contribution of €72 million
4	 Total consideration on a All acquisitions are accrete 	ending €357 million; including earn-o cquisitions was approx. €363 million etive to ordinary EPS in year 1 I to cover their cost of capital withir	(excl. NDC/IM)
	🕽 Wolters Kluwer	2005	Results March 1, 2006 - Amsterdam 36



Key Operational Measures	Actual 2005	Target 2006*		Free Cash Flow 2006 Improved growth
Organic revenue growth	2%	2-3%		 Margin improvement
Ordinary EBITA margin	16%	16.5-17.0%		 Maintain working capital improvement
Cash conversion	106%	95-105%	/ /	Premium redemption
Key Financial Measures			/ I	convertible bond
Free cash flow	€351 mln	€350mln		
ROIC %**	7%	7%		Ordinary diluted EPS
Ordinary diluted EPS	€1.06	€1.18 - €1.23		>10% increase
			•	(€0.03 NDC)





Key Operational Measures	2004	2005	2006E*	2007 Onwards*
Organic Revenue growth	1%	2%	2-3%	4%
Ordinary EBITA margin	16%	16%	16.5%-17.0%	19-20%
Cash conversion	126%	106%	95-105%	95-105%
Key Financial Measures				
Free cash flow	€456 mln	€351 mln	±€350 mln	≥€400 mln
ROIC %**	7%	7%	7%	≥ WACC
Ordinary diluted EPS	€1.02	€1.06	€1.18-€1.23	€1.45-€1.55







